Opportunity Information: Apply for SOL 621 14 000015
Apply for SOL 621 14 000015
- The Tanzania USAID Dar es Salaam in the health sector is offering a public funding opportunity titled "Comprehensive Community HIV Prevention Program for Key and Vulnerable Populations (CP2)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 98.001 USAID Foreign Assistance for Programs Overseas.
- This funding opportunity was created on Jul 18, 2014 and posted on Jul 18, 2014.
- Applicants must submit their applications by Aug 25, 2014 1200 East African Time (EAT) on August 25, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $73,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
- Qualified applicants may be U.S. private voluntary organizations (U.S. PVOs), Tanzanian or other non U.S. non governmental organizations (NGOs) or private, non profit organizations (or for profit companies willing to forego profits), including universities, research organizations, professional associations, and relevant special interest associations. Public International Organizations (PIOs) and faith based and community organizations are also eligible for award. In support of the Agency s interest in fostering a larger assistance base and expanding the number and sustainability of development partners, USAID encourages applications from potential new partners, particularly if they are joined with a more experienced organization.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Comprehensive Community HIV Prevention Program for Key and Vulnerable Populations (CP2) is a USAID/Tanzania cooperative agreement designed to help Tanzania reduce new HIV infections and improve overall population health in line with the Government of Tanzania (GoT) HIV prevention priorities. The core idea is to concentrate services in specific geographic areas and reach very high coverage, often described as "saturation," among groups at greatest risk. Rather than relying on a single intervention, CP2 emphasizes a combination prevention model that blends behavioral, biomedical, and structural approaches tailored to the realities of different populations and local HIV trends.
The opportunity prioritizes two broad categories of beneficiaries. Key populations include sex workers (SWs) and men who have sex with men (MSM), groups recognized as essential to address if the epidemic is to be slowed. Vulnerable populations include young women ages 15 to 24 who are at heightened risk, clients of sex workers, men in mobile occupations, and other locally defined high risk groups based on context and epidemiology. Across both categories, the program also intentionally reaches people living with HIV (PLHIV) to support healthy, dignified living and to reduce onward transmission, reflecting a prevention approach that includes treatment linkage and retention.
Program activities focus heavily on community-based delivery and peer-driven models, especially for SWs and MSM, while aligning with GoT, PEPFAR, and internationally recommended policies for these groups. Expected elements include peer-led outreach; integrated community services supported by drop-in centers; condom and lubricant distribution; and community-based HIV testing and counseling (CBHTC). The program also incorporates family planning (FP) services and community-based care, along with referrals for diagnosis and treatment of sexually transmitted infections (STIs) and tuberculosis (TB). A major operational requirement is that individuals who test HIV positive through CBHTC are not simply referred in a passive way; they must be trackably and measurably linked to facility-based HIV care, treatment, and family planning services. CP2 also plans active collaboration with health facilities to find and support HIV positive clients who have been lost to follow-up and bring them back into care.
For individuals who test HIV negative, CP2 is structured to go beyond delivering a negative result and stop there. They are expected to receive support for risk reduction planning and navigation to other prevention and health services in both community and facility settings, including voluntary medical male circumcision (VMMC) where appropriate. The emphasis on "innovative, yet practical and measurable" referral and tracking systems is meant to ensure that people do not fall through the cracks and that priority populations consistently receive the appropriate package of interventions based on their risk profile and HIV status.
A defining feature of CP2 is its strong focus on community engagement and long-term ownership of HIV prevention. The program aims for community leaders, networks, businesses, civil society organizations (CSOs), and local government authorities (LGAs) to better understand their local epidemics, advocate for effective services, and help sustain prevention efforts. Over time, CP2 envisions more of the service and support burden being shared by public systems, private sector actors, and civil society, with communities addressing harmful social norms that increase HIV risk. Gender considerations are expected to be built into the program throughout, using a gender-conscious approach that promotes gender equity and meaningful male involvement rather than treating these as side activities.
Sustainability and learning are also central to the opportunity. USAID describes CP2 as an investment intended to generate long-term returns by strengthening durable systems, community capacity, and shared financing and implementation responsibilities. The program includes a robust learning agenda to guide implementation decisions, contribute to Tanzania's broader HIV prevention response, and document outcomes. One highlighted evidence gap is the need to demonstrate what effective structural interventions look like in Tanzania and how defined geographic areas can progressively reach saturated coverage with a combination prevention package, providing practical lessons that can inform policy and scale-up.
From a funding and administrative perspective, the grant is a discretionary funding opportunity under a cooperative agreement, meaning USAID expects substantial involvement in guiding and overseeing implementation. USAID anticipates making one award with a very large total value, with an award floor of USD 64,000,000 and a ceiling of USD 73,000,000. Cost sharing or matching is required. The opportunity is identified as SOL-621-14-000015 under CFDA 98.001 (USAID Foreign Assistance for Programs Overseas). It was posted July 18, 2014, and the closing deadline was August 25, 2014 at 12:00 East African Time, with an archive date of September 24, 2014.
Eligibility is broadly open ("unrestricted") but targeted to qualified organizations capable of delivering complex, large-scale HIV prevention programming. Eligible applicants include U.S. private voluntary organizations (PVOs), Tanzanian and other non-U.S. NGOs, private nonprofit organizations, universities, research organizations, professional associations, special interest associations, public international organizations, and faith-based or community organizations. For-profit firms can apply if they are willing to forgo profit. USAID explicitly encourages applications from newer partners, particularly when paired with more experienced organizations, reflecting an interest in expanding and sustaining Tanzania's development partner base. The issuing agency is USAID Tanzania in Dar es Salaam, and the contact listed in the notice is Galina Ponkratova, Contract Specialist and Acquisition and Assistance Specialist.
Frequently Asked Questions (FAQs) - Comprehensive Community HIV Prevention Program for Key and Vulnerable Populations (CP2)
1) What is the CP2 grant opportunity?
The Comprehensive Community HIV Prevention Program for Key and Vulnerable Populations (CP2) is a USAID/Tanzania cooperative agreement designed to help Tanzania reduce new HIV infections and improve overall population health in line with Government of Tanzania (GoT) HIV prevention priorities.
2) What is the main approach CP2 is trying to achieve?
CP2 is built around concentrating services in specific geographic areas and reaching very high coverage (often described as "saturation") among people at greatest risk of HIV. The program emphasizes a combination prevention model that blends behavioral, biomedical, and structural approaches and adapts them to local population needs and HIV trends.
3) What does "combination prevention" mean in this opportunity?
In CP2, "combination prevention" refers to using multiple, coordinated interventions rather than relying on a single activity. The opportunity describes a blend of behavioral, biomedical, and structural approaches tailored to the realities of different populations and local epidemiology.
4) Which populations are prioritized as direct beneficiaries?
The opportunity prioritizes two broad categories: key populations and vulnerable populations. Key populations include sex workers (SWs) and men who have sex with men (MSM). Vulnerable populations include young women ages 15 to 24, clients of sex workers, men in mobile occupations, and other locally defined high-risk groups based on context and epidemiology.
5) Does CP2 include people living with HIV (PLHIV) in its scope?
Yes. CP2 intentionally reaches people living with HIV (PLHIV) to support healthy, dignified living and reduce onward transmission. The prevention approach described includes linkage to treatment and retention in care.
6) What kinds of service delivery models does CP2 emphasize?
CP2 emphasizes community-based delivery and peer-driven models, especially for sex workers and MSM, while aligning with GoT, PEPFAR, and internationally recommended policies for these populations.
7) What are examples of expected program activities under CP2?
Expected elements include peer-led outreach; integrated community services supported by drop-in centers; condom and lubricant distribution; and community-based HIV testing and counseling (CBHTC).
8) Are family planning services included in the CP2 program design?
Yes. The opportunity states that CP2 incorporates family planning (FP) services and community-based care.
9) Does CP2 address other health conditions besides HIV?
Yes. The program description includes referrals for diagnosis and treatment of sexually transmitted infections (STIs) and tuberculosis (TB), alongside HIV-focused prevention and linkage services.
10) What does CP2 require when someone tests HIV positive through community-based testing?
A key operational requirement is that people who test HIV positive through CBHTC must be trackably and measurably linked to facility-based HIV care and treatment (and family planning services), rather than receiving only a passive referral.
11) How does CP2 plan to support people who have been lost to follow-up in HIV care?
CP2 is expected to actively collaborate with health facilities to find and support HIV-positive clients who have been lost to follow-up and bring them back into care.
12) What does CP2 expect for individuals who test HIV negative?
For individuals who test HIV negative, CP2 is designed to go beyond delivering a negative result. The opportunity expects risk-reduction planning and navigation to other prevention and health services in community and facility settings, including voluntary medical male circumcision (VMMC) where appropriate.
13) Why does CP2 emphasize referral and tracking systems?
The opportunity calls for "innovative, yet practical and measurable" referral and tracking systems to help ensure people do not fall through the cracks and that priority populations consistently receive the right package of interventions based on risk profile and HIV status.
14) What role do drop-in centers play in the program?
Drop-in centers are described as a support platform for integrated community services, particularly within community-based and peer-driven delivery models.
15) How does CP2 define or describe "saturation" coverage?
The opportunity describes saturation as reaching very high coverage levels in defined geographic areas among populations at greatest risk, supported by a combination prevention package.
16) What does CP2 say about community engagement and ownership?
CP2 has a strong focus on community engagement and long-term ownership. It aims for community leaders, networks, businesses, CSOs, and local government authorities (LGAs) to better understand local epidemics, advocate for effective services, and help sustain prevention efforts over time.
17) How does CP2 approach sustainability?
USAID describes CP2 as an investment meant to generate long-term returns by strengthening durable systems, building community capacity, and increasing shared financing and implementation responsibilities across public systems, private sector actors, and civil society.
18) Are gender considerations explicitly expected in CP2?
Yes. Gender considerations are expected to be built into the program throughout using a gender-conscious approach that promotes gender equity and meaningful male involvement, rather than treating gender as a side activity.
19) What is the learning agenda or evidence focus described for CP2?
The opportunity includes a robust learning agenda intended to guide implementation decisions, contribute to Tanzania's broader HIV prevention response, and document outcomes. One highlighted evidence gap is demonstrating what effective structural interventions look like in Tanzania and how geographic areas can progressively achieve saturated coverage with a combination prevention package.
20) What type of award is CP2 and what does that imply?
CP2 is a discretionary funding opportunity under a cooperative agreement. This means USAID expects substantial involvement in guiding and overseeing implementation.
21) How many awards does USAID anticipate making under this opportunity?
USAID anticipates making one award.
22) What is the estimated funding range for the CP2 award?
The opportunity lists an award floor of USD 64,000,000 and a ceiling of USD 73,000,000, indicating a very large total value.
23) Is cost sharing or matching required?
Yes. Cost sharing or matching is required under this opportunity.
24) What is the solicitation number and CFDA listing for CP2?
The opportunity is identified as SOL-621-14-000015 under CFDA 98.001 (USAID Foreign Assistance for Programs Overseas).
25) When was the opportunity posted and when did it close?
It was posted July 18, 2014, and the closing deadline was August 25, 2014 at 12:00 East African Time. The archive date is September 24, 2014.
26) Who is eligible to apply?
Eligibility is described as "unrestricted" but aimed at qualified organizations capable of complex, large-scale HIV prevention programming. Eligible applicants include U.S. private voluntary organizations (PVOs), Tanzanian and other non-U.S. NGOs, private nonprofit organizations, universities, research organizations, professional associations, special interest associations, public international organizations, and faith-based or community organizations.
27) Can a for-profit organization apply?
Yes. For-profit firms can apply if they are willing to forgo profit.
28) Does USAID encourage applications from newer partners?
Yes. USAID explicitly encourages applications from newer partners, particularly when paired with more experienced organizations, reflecting an interest in expanding and sustaining Tanzania's development partner base.
29) Which USAID office is issuing this opportunity and where is it located?
The issuing agency is USAID Tanzania in Dar es Salaam.
30) Who is the contact person listed in the notice?
The contact listed is Galina Ponkratova, Contract Specialist and Acquisition and Assistance Specialist.
Browse more opportunities from the same category: Health
Next opportunity: NINDS CREATE Bio Development Track Preclinical and Early phase Clinical Development for Biotechnology Products and Biologics (UH2/UH3)
Previous opportunity: NINDS CREATE Bio Development Track Preclinical and Early phase Clinical Development for Biotechnology Products and Biologics (U44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for SOL 621 14 000015
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (SOL 621 14 000015) also looked into and applied for these:
| Funding Opportunity |
|---|
| NINDS CREATE Bio Development Track Preclinical and Early phase Clinical Development for Biotechnology Products and Biologics (UH2/UH3) Apply for PAR 14 288 Funding Number: PAR 14 288 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U01) Apply for RFA AI 14 048 Funding Number: RFA AI 14 048 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| AHRQ Health Services Research Demonstration and Dissemination Grants (R18) Apply for PA 14 290 Funding Number: PA 14 290 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| AHRQ Health Services Research Projects (R01) Apply for PA 14 291 Funding Number: PA 14 291 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| Immunobiology of Xenotransplantation (U19) Apply for RFA AI 14 047 Funding Number: RFA AI 14 047 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Mucosal Environment and HIV Prevention (MEHP II) (R01) Apply for RFA AI 14 036 Funding Number: RFA AI 14 036 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Strengthening Voluntary Medical Male Circumcision (MMC), Early Infant Male Circumcision (EIMC) and Pre Service Education in Lesotho Apply for RFA 674 14 000002 Funding Number: RFA 674 14 000002 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $23,800,000 |
| Enhance global health security and advance International Health Regulations (2005) Apply for EP IDS 14 013 Funding Number: EP IDS 14 013 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $1,000,000 |
| NIH Transformative Research Awards (R01) Apply for RFA RM 14 003 Funding Number: RFA RM 14 003 Agency: National Institutes of Health Category: Health Funding Amount: $15,000,000 |
| Enhance global health security and support International Health Regulations (2005) Apply for EP IDS 14 012 Funding Number: EP IDS 14 012 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $120,000 |
| Bioreactors for Reparative Medicine SBIR Direct Phase II (R44) Apply for RFA HL 15 017 Funding Number: RFA HL 15 017 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Bioreactors for Reparative Medicine (R41/R42) Apply for RFA HL 15 004 Funding Number: RFA HL 15 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bioreactors for Reparative Medicine (R43/R44) Apply for RFA HL 15 008 Funding Number: RFA HL 15 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Clinical Scientist Development Award in Aging (K08) Apply for RFA AG 15 016 Funding Number: RFA AG 15 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Patient Oriented Research Career Development Award in Aging (K23) Apply for RFA AG 15 017 Funding Number: RFA AG 15 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Clinical Studies on the Path to 510(k) (UH2/UH3) Apply for PAR 14 295 Funding Number: PAR 14 295 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Clinical Studies on the Path to 510(k) (U44) Apply for PAR 14 296 Funding Number: PAR 14 296 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Clinical Studies to Inform Final Device Design (UH2/UH3) Apply for PAR 14 297 Funding Number: PAR 14 297 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Early Feasibility Studies on the Path to Pre Market Approval (PMA) or Humanitarian Device Exemption (HDE) (UH2/UH3) Apply for PAR 14 298 Funding Number: PAR 14 298 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Early Feasibility Studies on the Path to Pre Market Approval (PMA) or Humanitarian Device Exemption (HDE) (U44) Apply for PAR 14 299 Funding Number: PAR 14 299 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "SOL 621 14 000015", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.